LUND, Sweden, May 22, 2023 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia") published the notice to the Annual General
Meeting 2023 on 25 April 2023
together with the Nomination Committee's motivated statement which
included the Nomination Committee's proposals for board members.
The Nomination Committee has now been informed that Helge Lubenow, Sven Andréasson and Vanessa Rollings will not stand for election as
board members in Immunovia. In addition, Philipp von Hugo has previously resigned from
the Board of Directors and is thus not available for re-election as
a board member.
Against this background, the Nomination Committee has presented
an updated proposal. In addition to the previously proposed
re-election of Peter Høngaard Andersen, the Nominating committee
additionally now proposes re-election of Hans Johansson and Martin Møller and new
election of Michael Löfman, respectively, as members of the board
of directors of Immunovia for the period until the end of the
annual general meeting 2024. Consequently, the number of board
members shall be four (4) instead of five (5) board members as
previously proposed. Information about the proposed board members
is, in addition to the information regarding Michael Löfman below,
available on Immunovia's webpage.
Michael Löfman
Michael Löfman has a Master of Science (MSc) in Economics and
Business Administration from the University of Uppsala (1989) and
has extensive experience working in the financial sector with
valuation and market research. He started his career as an
investment analyst with different brokers and asset managers and
has held various positions with Swedish Credit Insurance, Swedbank
Markets, Trygg-Hansa Asset Management, and SEB Investment
Management. 2004-2014 he worked as a Portfolio Manager and CEO for
Fat Tail Capital AG in Switzerland
with a focus on small- and midcaps, and a strategy based on
fundamental research, long-short, with a long bias. Since 2014 he
has worked with private investments mainly within real estate and
listed, as well as unlisted companies.
Michael Löfman is independent in relation to the company, the
company's management and the company's major
shareholders.
Michael Löfman currently holds 587,532 shares in
Immunovia.
The Annual General Meeting will take place on Friday
26 May 2023 at 9:00 am in The Spark, Scheeletorget 1, Medicon
Village, Lund. Entrance and
registration starts at 08:45. Registration for participation in the
annual general meeting expires at midnight on May 22, 2023.
For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
The information was submitted for publication, through the
agency of the contact person set out above, at 18:30 CET on 22 May
2023.
About Immunovia
Immunovia is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer
groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated, addressable market size of 1.8 million individuals per
year who could benefit from our test.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
The following files are available for download:
|
https://mb.cision.com/Main/13121/3772903/2074387.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/changes-to-the-nomination-committees-proposal-to-the-annual-general-meeting-2023-in-immunovia-ab-publ-301831102.html